Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 49

The DOI matches its Crossref record.

Mitochondrial Comparative Proteomics of Human Ovarian Cancer Cells and Their Platinum-resistant Sublines

Dai, Zhiqin, Yin, Jie, He, Haojie, Li, Wenrui, Hou, Chunmei, Qian, Xiaohong, Mao, Ning, Pan, Lingya·2010·PROTEOMICS
DOI 10.1002/pmic.200900685
Open this paper in CoChat — free account

Abstract

Resistance to platinum‐based chemotherapy is the major obstacle to successful treatment of ovarian cancer. It is evident that mitochondrial defects and the dysfunctions of oxidative phosphorylation and energy production in ovarian cancer cells were directly related to their resistance to platinum drugs. Using 2‐D DIGE, we compared mitochondrial proteins from two platinum‐sensitive human ovarian cancer cell lines (SKOV3 and A2780) with that of four platinum‐resistant sublines (SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP). Among the 236 differentially expressed spots, five mitochondrial proteins (ATP‐α, PRDX3, PHB, ETF, and ALDH) that participate in the electron transport respiratory chain were identified through mass spectrometry. All of them are downregulated in one or two of the platinum‐resistant cell lines. Three proteins (ATP‐α, PRDX3, and PHB) were validated by using western blot and immunohistochemistry. There is a significant decrease of PHB in tumor tissues from ovarian cancer patients who were resistant to platinum‐based chemotherapies. This is the first direct mitochondrial proteomic comparison between platinum‐sensitive and resistant ovarian cancer cells. These studies demonstrated that 2‐D DIGE‐based proteomic analysis could be a powerful tool to investigate limited mitochondrial proteins, and the association of PHB expression with platinum resistance indicates that mitochondria defects may contribute to platinum resistance in ovarian cancer cells.

Overview

Integrity signals

Registry

Crossref · 10.1002/pmic.200900685

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 49

  1. 10.3322/CA.2007.0010 · DOI
  2. 10.1016/S1535-6108(03)00058-8 · DOI
  3. 10.1016/S1368-7646(03)00059-1 · DOI
  4. 10.1158/1078-0432.CCR-0482-3 · DOI
  5. 10.1016/S0029-7844(98)00054-4 · DOI
  6. 10.1016/j.ctrv.2006.09.006 · DOI
  7. 10.1161/01.RES.0000179773.18195.12 · DOI
  8. Wang X., 2001, The expanding role of mitochondria in apoptosis, Genes Dev., 15, 2922
  9. 10.2174/156800909788166600 · DOI
  10. 10.1158/1078-0432.CCR-06-1037 · DOI
  11. 10.1016/j.tox.2009.01.022 · DOI
  12. Saitou M., 2009, Mitochondrial ultrastructure‐associated chemotherapy response in ovarian cancer, Oncol. Rep., 21, 199
  13. 10.1158/1541-7786.MCR-07-2130 · DOI
  14. Andrews P. A., 1992, Mitochondrial defects in cis‐diamminedichloroplatinum(II)‐resistant human ovarian carcinoma cells, Cancer Res., 52, 1895
  15. Yan X. D., 2006, Objective to explore the different mechanisms of to cisplatin (CDDP) resistance in human epithelial ovarian cancer cell lines by two different methods, Basic Clin. Med., 26, 739
  16. Li L., 2004, Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma, Int. J. Mol. Med., 14, 257
  17. 10.1007/BF00336786 · DOI
  18. 10.1007/978-1-59745-365-3_5 · DOI
  19. 10.1016/j.bbabio.2008.04.009 · DOI
  20. 10.1016/0003-2697(90)90463-J · DOI
  21. 10.2183/pjab1945.36.372 · DOI
  22. 10.1021/ac950914h · DOI
  23. 10.1007/s00125-007-0627-y · DOI
  24. Kurtz A., 2004, Somatic mitochondrial DNA mutations in neurofibromatosis type 1‐associated tumors, Mol. Cancer Res., 2, 433, 10.1158/1541-7786.433.2.8 · DOI
  25. 10.1172/JCI114537 · DOI
  26. Swenerton K., 1998, Salvage chemotherapy for refractory disease in Ovarian Cancer Controversies on Management, 169
  27. 10.1016/j.bbapap.2008.09.017 · DOI
  28. 10.1021/pr050084g · DOI
  29. 10.1016/S0027-5107(97)00223-6 · DOI
  30. 10.1080/10408360500295477 · DOI
  31. 10.1038/nbt793 · DOI
  32. 10.1146/annurev.genet.33.1.351 · DOI
  33. 10.1074/mcp.M300117-MCP200 · DOI
  34. 10.1074/mcp.M400079-MCP200 · DOI
  35. 10.1016/j.freeradbiomed.2005.05.013 · DOI
  36. 10.1002/pmic.200700795 · DOI
  37. 10.1016/S0076-6879(05)02008-2 · DOI
  38. 10.1023/A:1020959106412 · DOI
  39. 10.1038/35015709 · DOI
  40. 10.1007/978-3-642-56895-4 · DOI
  41. 10.1002/elps.1150181133 · DOI
  42. 10.1021/pr060402r · DOI
  43. 10.1016/j.bbamcr.2008.05.013 · DOI
  44. 10.4161/cbt.5.7.2975 · DOI
  45. 10.1038/sj.onc.1205551 · DOI
  46. 10.1002/ijc.23351 · DOI
  47. 10.1016/j.tem.2009.04.004 · DOI
  48. Yan X. D., 2007, Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations, Oncol. Rep., 17, 1163
  49. 10.1016/0168-9525(93)90068-S · DOI

Cited by

Metadata

Authors
Dai, Z., Yin, J., He, H., Li, W., Hou, C., Qian, X., Mao, N., & Pan, L.
Venue
PROTEOMICS
Publisher
Wiley
Published
2010-10-19
Volume
10
Issue
21
Pages
3789-3799
ISSN
  • 1615-9853
  • 1615-9861
DOI
10.1002/pmic.200900685
Cited by
49
References
0
Language
en
Update notices
erratum (2011-02-21)
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.